REDWOOD CITY, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies that support the use of quantitative real-time polymerase chain reaction (RT-PCR), as performed in the Oncotype DX assay, for measuring the hormone receptors, estrogen receptor (ER) and progesterone receptor (PR) in early breast cancer patients. A separate study identified multiple genes, including the 21 genes in Oncotype DX, that may predict the risk of breast cancer recurrence following adjuvant chemotherapy. These data were presented at the 2007 ASCO Breast Cancer Symposium that took place in San Francisco, California on September 7 and 8.
"We're pleased to participate in ASCO's inaugural forum dedicated to cutting-edge scientific research in breast cancer," said Steven Shak, M.D., chief medical officer of Genomic Health. "We believe the consistent results seen in both the Kaiser Permanente and ECOG studies indicate that quantitative RT-PCR is a reliable method for determining hormone receptor status in breast cancer."
Following are details for each study presented at the meeting:
-- Abstract #88
Poster presentation: A Kaiser-Permanente Population-Based Study of ER
and PR Expression by the Standard Method, Immunohistochemistry (IHC),
Compared to a New Method, Quantitative Reverse Polymerase Chain
Presenter: Frederick L. Baehner, M.D.
Summary: A comparison of IHC, the methodology that is routinely used,
to quantitative RT-PCR by Oncotype DX demonstrated a high degree of
agreement in the assessment of estrogen receptor (ER), progesterone
receptor (PR) and hormone (HR
|SOURCE Genomic Health, Inc.|
Copyright©2007 PR Newswire.
All rights reserved